Opinion|Videos|January 17, 2025
JAK Inhibition in Polycythemia Vera: Treatment Updates
Panelists discuss the role of JAK inhibition in the treatment of polycythemia vera (PV), focusing on the latest efficacy data for ruxolitinib (RUX) from studies such as RUX vs best available therapy (BAT) in PV and the MAJIC-PV trial, highlighting its impact on treatment outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How would you describe the role of JAK inhibition for patients with PV?
- Please comment on the latest efficacy data of ruxolitinib (RUX) in PV.
Advertisement
Related to this article
Cathy Eng, MD, FACP, FASCO, discusses how oncology fellows can navigate the journal submission and review process.
ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.
The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.
The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.
SOT106 earned an FDA fast track designation for advanced or recurrent soft tissue sarcoma.
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.
The pertuzumab biosimilar TQB2440 met equivalence margins for tpCR vs reference pertuzumab in ER/PR-negative, HER2-positive early breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daraxonrasib for Metastatic Pancreatic Ductal Adenocarcinoma
2
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
3
ASCO Issues Warning Regarding Ifosfamide Shortage for Cancer Care
4
Dr Ayanambakkam on the Safety of Darlifarnib Plus Cabozantinib in RCC KD
5